Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
Provided By PR Newswire
Last update: Jun 13, 2025
Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease
Read more at prnewswire.com152.41
+0.4 (+0.26%)
Find more stocks in the Stock Screener
JNJ Latest News and Analysis
11 days ago - ChartmillJohnson & Johnson (NYSE:JNJ) - A Reliable Dividend Stock Worth ConsideringJohnson & Johnson (NYSE:JNJ) is a top dividend stock with a 3.32% yield, strong profitability, and a reliable payout history, making it a solid choice for income investors.
